• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eyenovia looks to $35m IPO for ocular drug-delivery tech

December 20, 2017 By Sarah Faulkner

EyenoviaEyenovia is looking to raise up to $35 million in an initial public offering, according to recent filings. The company plans to use the funds to support trials of its device, which is designed to deliver small doses of drugs to the eye.

The New York-based company uses a piezo-electric dispensation technology to deliver microdoses of drugs topically to the eye. The device tracks patient compliance and is designed to help avoid the adverse events linked to treating eye diseases, which Eyenovia hypothesizes are due to the large volume of drug delivered by traditional eye droppers.

According to regulatory filings, Eyenovia plans to use the $7.4 million it has on-hand plus the cash from its IPO to finish Phase III trials for MicroProst, its chronic angle closure glaucoma product, and for MicroStat, a product used to dilate the eyes during an eye exam.

The 7-person company said it is pursuing a 505(b)(2) pathway since only the drug comes into contact with the body.

As it moves forward with its clinical programs, Eyenovia is also in the midst of a legal spat that began after the company purchased Corinthian Ophthalmic’s assets. Eyenovia’s chief executive, Dr. Tsontcho Ianchulev, and two board members were involved in both Eyenovia and Corinthian.

A Corinthian shareholder has alleged a fraudulent transfer, according to the company’s filings, but Eyenovia said it doesn’t anticipate suffering a material loss as a result of the case. The two parties held a settlement conference this year, but are “not close to agreement on a settlement,” Eyenovia wrote.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Initial Public Offering (IPO), Optical/Ophthalmic, Pharmaceuticals Tagged With: Eyenovia Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS